Aligos Therapeutics extended its headquarters Lease through March 31, 2034, with monthly base rent reaching $5.716 per rentable square foot in the final lease year. The agreement matters to investors because it establishes future occupancy costs, provides rent abatement from April 1, 2027 to January 31, 2028, and creates specified termination options.

Key Highlights

  • The First Amendment extends the headquarters lease from March 31, 2027 to March 31, 2034.
  • Rent abatement applies from April 1, 2027 to January 31, 2028, subject to the lease remaining free of material default.
  • Aligos can terminate the lease as of March 31, 2031 by paying $2,476,429.22 under the stated option.

The First Amendment extends Aligos Therapeutics, Inc. (NASDAQ: ALGS)’s headquarters lease at One Corporate Drive in South San Francisco through March 31, 2034. Monthly base rent per rentable square foot begins at $4.650 from April 1, 2027 to March 31, 2028.

Lease Schedule Adds Rent Relief and Exit Rights

The agreement requires Aligos Therapeutics to pay a specified percentage of certain landlord-paid expenses. Aligos may end the lease as of March 31, 2031 by delivering written notice on or before March 31, 2030 and paying $2,476,429.22 by the termination date. The amendment revises the existing extension option to one seven-year option for the period immediately following the extended lease term. The Lease is dated June 21, 2018, and the amendment was entered into with Britannia Biotech Gateway Limited Partnership.